Report and Financial Statements

31 December 2008

A8UCLCPA A53 25/08/2009 COMPANIES HOUSE

REPORT AND FINANCIAL STATEMENTS 2008

CONTENTS	Page
Officers and professional advisers	1
Directors' report	2
Independent auditors' report	4
Profit and loss account	6
Balance sheet	7
Notes to the financial statements	8

OFFICERS AND PROFESSIONAL ADVISERS

DIRECTORS

Christopher Newton Onno van de Stolpe

SECRETARY

Johan Gustaaf Cyriel Van den Eynde

REGISTERED OFFICE

Chesterford Research Park Saffron Walden Essex CB10 1XL

AUDITORS

Deloitte LLP Chartered Accountants and Registered Auditors Cambridge

DIRECTORS' REPORT

The directors present their annual report and the audited financial statements for the year ended 31 December 2008.

This directors' report has been prepared in accordance with the special provisions relating to small companies under section 246(4) of the Companies Act 1985.

PRINCIPAL ACTIVITY AND BUSINESS REVIEW

The company did not trade during the year and is expected to remain non-trading for the foreseeable future.

SUBSEQUENT EVENTS AND GOING CONCERN

Since the balance sheet date, the directors have commenced a process to liquidate the company. The financial statements have therefore been prepared on a basis other than that of a going concern, as explained more fully in note 1 to the financial statements.

DIRECTORS

The directors who served throughout the year were:

C G Newton
O van de Stolpe

DIRECTORS' INDEMNITIES

The company has made qualifying third party indemnity provisions for the benefit of its directors which were made during the year and remain in force at the date of this report.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- · make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for the system of internal control, safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

DIRECTORS' REPORT

AUDITORS

In the case of each of the persons who are directors of the company at the date when this report is approved:

- so far as each of the directors is aware, there is no relevant audit information (as defined in the Companies Act 1985) of which the company's auditors are unaware; and
- each of the directors has taken all the steps that they ought to have taken as a director to make themselves aware of any relevant audit information (as defined) and to establish that the company's auditors are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s234ZA of the Companies Act 1985.

Deloitte LLP have expressed their willingness to continue in office as auditors and a resolution to reappoint them will be proposed at the forthcoming Annual General Meeting.

Approved by the Board of Directors and signed on behalf of the Board

C Newton Director

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF CAMBRIDGE DISCOVERY LIMITED

We have audited the financial statements of Cambridge Discovery Limited for the year ended 31 December 2008 which comprise the profit and loss account, the balance sheet and the related notes 1 to 14. These financial statements have been prepared under the accounting policies set out therein.

This report is made solely to the company's members, as a body, in accordance with section 235 of the Companies Act 1985. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of directors and auditors

The directors' responsibilities for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Directors' Responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the information given in the Directors' Report is consistent with the financial statements.

In addition we report to you if, in our opinion, the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed.

We read the Directors' Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF CAMBRIDGE DISCOVERY LIMITED (continued)

Opinion

In our opinion:

- the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the company's affairs as at 31 December 2008 and of its loss for the year then ended:
- the financial statements have been properly prepared in accordance with the Companies Act 1985; and
- the information given in the Directors' Report is consistent with the financial statements.

Emphasis of matter - Financial statements prepared other than on a going concern basis

In forming our opinion on the financial statements, which is not qualified, we have considered the adequacy of the disclosure made in note 1 to the financial statements, which explains that the financial statements have been prepared on a basis other than that of a going concern.

Deloitte LLP

Delotte Les

Chartered Accountants and Registered Auditors Cambridge, United Kingdom

2, Ayust 2009

PROFIT AND LOSS ACCOUNT Year ended 31 December 2008

	Note	2008 £	2007 £
Operating loss Interest payable and similar charges	4	(214,917)	(240,867)
LOSS ON ORDINARY ACTIVITIES BEFORE TAXATION		(214,917)	(240,867)
Tax on loss on ordinary activities	5		
LOSS FOR THE FINANCIAL YEAR	10	(214,917)	(240,867)

All activities derive from continuing operations.

There are no recognised gains and losses for the current financial year and preceding financial year other than as stated in the profit and loss account.

BALANCE SHEET 31 December 2008

Note	2008 £	2007 £
6	27,539,331	27,539,331
7	(7,581,966)	(7,581,966)
	19,957,365	19,957,365
8	(3,146,904)	(3,146,904)
	16,810,461	16,810,461
	-	
9	1.000	1,000
10	•	1,978,800
10	14,830,661	14,830,661
11	16,810,461	16,810,461
	6 7 8 9 10 10	Note £ 6 27,539,331 7 (7,581,966) 19,957,365 8 (3,146,904) 16,810,461 9 1,000 10 1,978,800 10 14,830,661

These financial statements were approved by the Board of Directors and authorised for issue on 20 August 2009
They were signed on its behalf by

C Newton Director

NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2008

1. ACCOUNTING POLICIES

The financial statements are prepared in accordance with applicable United Kingdom accounting standards. The particular accounting policies adopted are described below.

Accounting convention

The financial statements are prepared under the historical cost convention.

Going concern

Since the balance sheet date, the directors have commenced a process to liquidate the company.

As required by FRS 18 'Accounting Policies', the directors have prepared the financial statements on the basis that the company is no longer a going concern. No material adjustments arose as a result of ceasing to apply the going concern basis.

The directors consider that the company will be able to meet its intercompany obligations, for the reasons explained below:

- the company's only liabilities comprise an amount of £7,581,966 owed to Cambridge Drug Discovery Holdings Limited, its immediate parent company, and preference shares amounting to £3,146,904; and
- the directors have received a letter of intent from the directors of Cambridge Drug Discovery Holdings Limited that they will not seek repayment of the amounts owed to them for a period of at least 12 months from the date of approval of these financial statements or until such time as the obligations can be settled by way of the outstanding intercompany debtor, for an amount of £27,539,331.

The financial statements do not contain any adjustments that would result in the event that the ultimate recoverability of the intercompany debtors was insufficient to discharge the intercompany liabilities referred to above.

Cash flow statement

Under FRS 1 (revised 1996) 'Cash flow statements' the company is exempt from the requirement to prepare a cash flow statement on the grounds that a parent undertaking includes the company in its own published consolidated financial statements.

2. AUDITORS' REMUNERATION

Auditors' remuneration of £1,000 (2007 - £1,000) was borne by BioFocus DPI Limited, an intermediate parent company, in both years.

3. EMPLOYEES AND DIRECTORS

The company did not have any employees in the current year or preceding year.

The directors received no emoluments for their services to the company (2007 - £nil).

NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2008

4.	INTEREST PAYABLE AND SIMILAR CHARGES		
		2008 £	2007 £
	Accrued preference dividend	214,917	240,867
5.	TAX ON LOSS ON ORDINARY ACTIVITIES		
	(a) Analysis of charge for the year:		
		2008 £	2007 £
	Current tax UK corporation tax	-	-
	Total current tax	-	-
	Total tax on loss on ordinary activities	_	-
	(b) Factors affecting tax charge for the year		
	The tax assessed for the year is different to the standard rate of corporation tax in (30%).	he UK of 28.5%	(2007 -
	The differences are explained below:		
		2008 £	2007 £
	Loss on ordinary activities before tax	(214,917)	(240,867)
	Loss on ordinary activities before tax at the standard rate of UK		
	corporation tax of 28.5% (2007: 30%) Expenses not deductible for tax purposes	(61,251) 61,251	(72,260) 72,260
	Current tax charge for the year		

c) Factors affecting tax charge for future years

The company has no losses for tax purposes (2007 - £nil) available to carry forward at 31 December 2008 against future profits.

NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2008

6. DEBTORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

		2008 £	2007 £
	Amount due from intermediate parent company	27,539,331	27,539,331
7.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2008 £	2007 £
	Amount owed to immediate parent company	7,581,966	7,581,966
8.	CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YE		
		2008 £	2007 £
	Preference shares	3,146,904	3,146,904
9.	CALLED UP SHARE CAPITAL		
		2008 £	2007 £
	Authorised: 10,000 ordinary shares of 10p each	1,000	1,000
	31,469,041 preference shares of 10p each (included in creditors - see note 8)	3,146,904	3,146,904
	Allotted, called up and fully paid 10,000 ordinary shares of 10p each	1,000	1,000
	31,469,041 preference shares of 10p each (included in creditors - see note 8)	3,146,904	3,146,904

NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2008

9. CALLED UP SHARE CAPITAL (continued)

The preference shares attract a cumulative preferential net cash dividend of 2.5% per annum above the Bank of England base rate, payable in arrears on 30 June and 31 December. The first payment was due on 31 December 2002 in respect of the period commencing from the date of issue.

The preference shares have priority over the ordinary shares for the return of the capital on liquidation or on a capital reduction. The preference shares confer no voting rights except in circumstances laid down in the Articles of Association of the company.

The company may redeem the preference shares at par in accordance with the terms of the Articles of Association.

10. STATEMENT OF MOVEMENTS ON RESERVES

	Share premium account £	Profit and loss account £
At 1 January 2008 Loss for the financial year Preference share dividend waived by shareholder	1,978,800	14,830,661 214,917 (214,917)
At 31 December 2008	1,978,800	14,830,661

11. RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS

	2008 £	2007 £
Loss for the financial year Dividend waiver	(214,917) 214,917	(240,867) 240,867
Opening shareholders' funds	16,810,461	16,810,461
Closing shareholders' funds	16,810,461	16,810,461

12. RELATED PARTY TRANSACTIONS

The company has taken advantage of the exemptions available to 90% subsidiaries under Financial Reporting Standard No 8 "Related party disclosures" not to disclose transactions with other group companies (or investees of the group qualifying as related parties).

NOTES TO THE FINANCIAL STATEMENTS Year ended 31 December 2008

13. SUBSEQUENT EVENTS

Since the balance sheet date, the directors have commenced a process to liquidate the company.

14. ULTIMATE PARENT COMPANY AND CONTROLLING PARTY

The company is a subsidiary undertaking of Cambridge Drug Discovery Holdings Limited, incorporated in England and Wales. The ultimate parent company and controlling party is Galapagos NV, incorporated in Belgium.

The largest and smallest group in which the results of the company are consolidated is that headed by Galapagos NV. The consolidated accounts of Galapagos NV are available to the public and may be obtained from Galapagos NV, General De Wittelaan, L11/A3, 2800 Mechelen, Belgium.